Ian Mortimer - 09 Jan 2026 Form 4 Insider Report for Xenon Pharmaceuticals Inc. (XENE)

Role
PRESIDENT & CEO, Director
Signature
/s/ Nathaniel Adams, Attorney-in-fact
Issuer symbol
XENE
Transactions as of
09 Jan 2026
Net transactions value
$0
Form type
4
Filing time
09 Jan 2026, 18:51:00 UTC
Previous filing
02 Jan 2026
Next filing
11 Mar 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
MORTIMER IAN PRESIDENT & CEO, Director 3650 GILMORE WAY, BURNABY, BRITISH COLUMBIA, CANADA /s/ Nathaniel Adams, Attorney-in-fact 09 Jan 2026 0001619961

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction XENE Share Option (Right to Buy) Award $0 +350,000 $0.000000 350,000 09 Jan 2026 Common Shares 350,000 $42.15 Direct F1
transaction XENE Restricted Share Units Award $0 +65,000 $0.000000 65,000 09 Jan 2026 Common Shares 65,000 $0.000000 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Vesting 25% on January 9, 2027, and 75% vesting thereafter over the course of the next 3 years, in equal amounts, on the last day of each month.
F2 Each restricted share unit represents a contingent right to receive one Common Share vesting 25% on each of the first four anniversaries of the date of grant, beginning on January 9, 2027.